Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Aria Vaishnavi"'
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-13 (2024)
Abstract In this review, we cover the current understanding of BRAF mutations and associated clinical characteristics in patients with metastatic NSCLC, approved and emerging treatment options, BRAF sequencing approaches, and unmet needs. The BRAFV60
Externí odkaz:
https://doaj.org/article/5d4d7a8e57754e16812b1b989f4ffe66
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/b01d9d85a526473fad40622c3a74faba
Autor:
Aria Vaishnavi, Michael T. Scherzer, Conan G. Kinsey, Gennie L. Parkman, Amanda Truong, Phaedra Ghazi, Sophia Schuman, Benjamin Battistone, Ignacio Garrido-Laguna, Martin McMahon
Publikováno v:
Cell Reports, Vol 32, Iss 5, Pp 107994- (2020)
Summary: NTRK1 gene fusions are actionable drivers of numerous human malignancies. Here, we show that expression of the TPR-NTRK1 fusion kinase in immortalized mouse pancreatic ductal epithelial (IMPE) (pancreas) or mouse lung epithelial (MLE-12) cel
Externí odkaz:
https://doaj.org/article/17c5dbf5b7bd4d12976eee924b66ab0f
Autor:
Kurtis D Davies, Sakshi Mahale, David P Astling, Dara L Aisner, Anh T Le, Trista K Hinz, Aria Vaishnavi, Paul A Bunn, Lynn E Heasley, Aik-Choon Tan, D Ross Camidge, Marileila Varella-Garcia, Robert C Doebele
Publikováno v:
PLoS ONE, Vol 8, Iss 12, p e82236 (2013)
The targeting of oncogenic 'driver' kinases with small molecule inhibitors has proven to be a highly effective therapeutic strategy in selected non-small cell lung cancer (NSCLC) patients. However, acquired resistance to targeted therapies invariably
Externí odkaz:
https://doaj.org/article/ac60de8b4c2f4279b38e26b9cd47f632
Autor:
Jennifer A. Low, Nisha Nanda, Michele Fernandes, Brian B. Tuch, Deborah Morosini, Philip J. Stephens, Yali Li, Dara L. Aisner, Marileila Varella-Garcia, Antonio Jimeno, Stephen Keysar, Adriana Estrada-Bernal, Anh T. Le, Aria Vaishnavi, Lara E. Davis, Robert C. Doebele
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36a66340cae723397120cc48c8d7507e
https://doi.org/10.1158/2159-8290.22529550.v1
https://doi.org/10.1158/2159-8290.22529550.v1
Autor:
Jennifer A. Low, Nisha Nanda, Michele Fernandes, Brian B. Tuch, Deborah Morosini, Philip J. Stephens, Yali Li, Dara L. Aisner, Marileila Varella-Garcia, Antonio Jimeno, Stephen Keysar, Adriana Estrada-Bernal, Anh T. Le, Aria Vaishnavi, Lara E. Davis, Robert C. Doebele
Supplementary Figure 1. Structure of LOXO-101. Supplementary Figure 2. Schematic for TRK-SHC1 proximity ligation assay (PLA). Supplementary Figure 3. Validation of the TRK-SHC1 PLA. Supplementary Figure 4. TRK and ALK PLA in an ALK+ tumor sample. Sup
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2127ca5310438ad8be46daccfdd01122
https://doi.org/10.1158/2159-8290.22529547.v1
https://doi.org/10.1158/2159-8290.22529547.v1
Autor:
Robert C. Doebele, Dara L. Aisner, Lynn E. Heasley, Antonio Jimeno, Eric B. Haura, Marileila Varella-Garcia, Kathryn E. Ware, Kurtis D. Davies, Natalia J. Sumi, Severine Kako, Matthew A. Smith, Magdalena J. Glogowska, Stephen B. Keysar, Anh T. Le, Lindsay A. Marek, Uwe Rix, Laura Schubert, Aria Vaishnavi
Table 1: Cell lines, fusions, tyrosine kinase inhibitors and targets. Table 2: IC50 values for Figure 1C and relative fold change.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6254dd69c7ef2b128f46e9a1b4e616c
https://doi.org/10.1158/0008-5472.22414859.v1
https://doi.org/10.1158/0008-5472.22414859.v1
Autor:
Robert C. Doebele, Dara L. Aisner, Lynn E. Heasley, Antonio Jimeno, Eric B. Haura, Marileila Varella-Garcia, Kathryn E. Ware, Kurtis D. Davies, Natalia J. Sumi, Severine Kako, Matthew A. Smith, Magdalena J. Glogowska, Stephen B. Keysar, Anh T. Le, Lindsay A. Marek, Uwe Rix, Laura Schubert, Aria Vaishnavi
Oncogenic kinase fusions of ALK, ROS1, RET, and NTRK1 act as drivers in human lung and other cancers. Residual tumor burden following treatment of ALK or ROS1+ lung cancer patients with oncogene-targeted therapy ultimately enables the emergence of dr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::830b24f41c5a103ad7adbab4bbba8e0f
https://doi.org/10.1158/0008-5472.c.6509096.v1
https://doi.org/10.1158/0008-5472.c.6509096.v1
Autor:
Robert C. Doebele, Dara L. Aisner, Lynn E. Heasley, Antonio Jimeno, Eric B. Haura, Marileila Varella-Garcia, Kathryn E. Ware, Kurtis D. Davies, Natalia J. Sumi, Severine Kako, Matthew A. Smith, Magdalena J. Glogowska, Stephen B. Keysar, Anh T. Le, Lindsay A. Marek, Uwe Rix, Laura Schubert, Aria Vaishnavi
Fig. S1: EGFR inhibition or stimulation affects normal and catalytically inactive fusion oncogene signaling. Fig. S2: EGFR knockdown reduces fusion kinase cancer cell proliferation. Fig. S3: Conserved re-phosphorylated activation loop tyrosines enabl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::779f86b37fb3645e01709ba4e535901f
https://doi.org/10.1158/0008-5472.22414862
https://doi.org/10.1158/0008-5472.22414862
Autor:
Martin McMahon, Michael B. Mann, Allie Grossmann, David J. Adams, Conan G. Kinsey, William A. Weiss, Alistair G. Rust, Karen Mann, Annie Liu, Justin Y. Newberg, Louise van der Weyden, Steven A. Chmura, Adam J. Dupuy, Christopher S. Hackett, Brandon Murphy, J. Edward Van Veen, Sophia Schuman, Michael T. Scherzer, Eric E. Gardner, Christopher Stehn, Maebh Jacob, Joseph Juan, Aria Vaishnavi
Mutationally activated BRAF is detected in approximately 7% of human lung adenocarcinomas, with BRAFT1799A serving as a predictive biomarker for treatment of patients with FDA-approved inhibitors of BRAFV600E oncoprotein signaling. In genetically eng
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::22219facb8d6a83ad63b275f44f70311
https://doi.org/10.1158/0008-5472.c.6514238.v1
https://doi.org/10.1158/0008-5472.c.6514238.v1